RLMD
RLMD
NASDAQ · Pharmaceuticals

Relmada Therapeutics Inc

$7.32
-0.11 (-1.48%)
As of May 9, 1:56 AM ET ·
Analyst Consensus
Strong Buy
11
Analysts
Moderate
Coverage
Buy 10 91%
Hold 1 9%
Sell 0 0%
Price Target
Analyst Price Target +410.5% upside
Low Target $22.23
Average Target $37.37
High Target $43.38
Current Price $7.32
Current
$7.32
Target
$37.37
$22.23 $37.37 avg $43.38
Scenario Analysis
Bear Case
$22.23
203.7%
Low target
Base Case
$37.37
+410.5%
Avg target
Bull Case
$43.38
+492.6%
High target
Risk/Reward
2.4x
Favorable
Price in Context
52-Week High
$8.00
-8.5% from high
52-Week Low
$0.32
+2,164.2% from low
Target vs 52W High
$37.37
+367.1% vs high
Next Earnings Report
May 12, 2026 · After Market Close
1d
tomorrow
EPS Est: $-0.20
Earnings in 1 days. Analyst targets may shift significantly after the report.
Peer Consensus — Pharmaceuticals
Stock Consensus Analysts Buy % Target Upside
RDY
Dr. Reddy's Laboratories
Hold 45 51% +0.0%
LLY
Eli Lilly and Co.
Strong Buy 39 77% $1,330.33 +40.3%
JNJ
Johnson & Johnson
Buy 32 63% $299.55 +35.3%
MRK
Merck & Co. Inc.
Buy 35 71% $159.27 +43.0%
PFE
Pfizer Inc.
Hold 36 44% $33.90 +32.0%
BMY
Bristol-Myers Squibb Co
Hold 36 42% $174.50 +210.7%
ZTS
Zoetis Inc
Buy 25 60% $209.87 +153.4%
RPRX
Royalty Pharma Plc- Cl A
Strong Buy 16 88% $36.26 -28.6%